Presentations.ai AI Slide Generator Automates Investor Pitch Decks and Sales PPTs for 12 Million Users – The AI PowerPoint Maker Scales Professional Slide Generation With Branding, Design and Data Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company…
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare
— Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives…
Cognition Therapeutics Announces Participation in March Investment Conferences
PURCHASE, N.Y., March 08, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical…
Adaptive Research and UBERDOC Announce Collaboration to Expand Clinical Trial Access to Physicians and Patients
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) — Adaptive Research, an integrated clinical trial site…
Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
Nes-Ziona, Israel, March 08, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022
DEER PARK, Ill., March 08, 2022 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (Nasdaq: ETON), an…
Ayala Pharmaceuticals, MD Anderson Cancer Center and the Adenoid Cystic Carcinoma Research Foundation Announce Initiation of Enrollment in Window of Opportunity Study of AL101 in Adenoid Cystic Carcinoma
Window of Opportunity Study is Evaluating AL101 Administered Prior to Surgery in Patients with Advanced,…
Science 37 to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022
RESEARCH TRIANGLE PARK, N.C., March 08, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:…
Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Media Release COPENHAGEN, Denmark; March 8, 2022 Genmab A/S (Nasdaq: GMAB) announced today that the…
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO;…
Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference
VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB”…
Organogenesis Holdings Inc. to Present at the Oppenheimer Healthcare Conference
CANTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
Neuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical…
BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)
PALO ALTO and SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc….
InMed to Present at the 34th Annual Roth Conference
Vancouver, BC, March 08, 2022 (GLOBE NEWSWIRE) — via InvestorWire — InMed Pharmaceuticals Inc. (“InMed”…
iSpecimen’s Global Biospecimen Marketplace Surpasses 200 Suppliers
– Proprietary Marketplace Provides Easy Access to Urgently-Needed Tissues, Biofluids and Cells for Lifesaving Medical…
Inozyme Pharma Strengthens Management Team with Two Executive Appointments
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare…
Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the Board of Directors
WALTHAM, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Affinia Therapeutics, an innovative gene therapy company…
XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events
Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study in metastatic pancreatic cancer…
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…